Table 5.
Univariate analysis of factors predictive of progression-free and overall survival
| Variable | No. of patients (n = 84) | Progression-free survival | Overall survival | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| B | SE | Wald | HR (95% CI) | P value* | B | SE | Wald | HR (95% CI) | P value* | ||
| Sex, F/M | 30/54 | 0.334 | 0.315 | 1.124 | 1.396 (0.753–2.588) | 0.289 | 0.374 | 0.323 | 1.342 | 1.454 (0.772–2.738) | 0.247 |
| Age, ≤ 60/> 60 | 43/41 | 0.513 | 0.304 | 2.841 | 1.670 (0.920–3.032) | 0.092 | 0.576 | 0.305 | 3.564 | 1.779 (0.978–3.236) | 0.059 |
| LDH level, normal/elevated | 38/46 | 0.679 | 0.310 | 4.790 | 1.972 (1.073–3.621) | 0.029 | 0.800 | 0.317 | 6.389 | 2.226 (1.197–4.141) | 0.011 |
| B symptoms, no/yes | 33/51 | 0.861 | 0.334 | 6.662 | 2.366 (1.230–4.550) | 0.010 | 0.840 | 0.341 | 6.072 | 2.317 (1.188–4.520) | 0.014 |
| ECOG PS, 0–1/≥ 2 | 57/27 | 1.055 | 0.300 | 12.337 | 2.873 (1.594–5.176) | < 0.001 | 0.999 | 0.301 | 10.986 | 2.715 (1.504–4.900) | 0.001 |
| Ann Arbor stage, I–II/III–IV | 15/69 | 0.867 | 0.477 | 3.300 | 2.379 (0.934–6.059) | 0.069 | 0.975 | 0.526 | 3.436 | 2.650 (0.946–7.429) | 0.064 |
| Extranodal sites ≥ 2, no/yes | 65/19 | 0.545 | 0.321 | 2.880 | 1.724 (0.919–3.233) | 0.090 | 0.494 | 0321 | 2.369 | 1.639 (0.874–3.075) | 0.124 |
| BMB, negative/positive | 63/21 | 0.652 | 0.310 | 4.430 | 1.920 (1.046–3.525) | 0.035 | 0.624 | 0.310 | 4.050 | 1.866 (1.016–3.427) | 0.044 |
| Ki-67 ≥ 80%, no/yes | 60/24 | 0.556 | 0.305 | 3.334 | 1.744 (0.960–3.169) | 0.068 | 0.517 | 0.306 | 2.854 | 1.678 (0.920–3.057) | 0.091 |
| Platelet cell count, ≥ 150 × 109/L | 48/36 | 0.594 | 0.300 | 3.923 | 1.812 (1.006–3.262) | 0.048 | 0.588 | 0.300 | 3.836 | 1.800 (1.000–3.240) | 0.050 |
| IPI, 0–2/3–5 | 47/37 | 1.148 | 0.313 | 13.475 | 3.153 (1.708–5.820) | < 0.001 | 1.143 | 0.314 | 13.287 | 3.136 (1.696–5.799) | < 0.001 |
| PIT, 0–1/2–4 | 41/43 | 1.068 | 0.317 | 11.316 | 2.909 (1.561–5.418) | 0.001 | 1.113 | 0.324 | 11.799 | 3.044 (1.613–5.744) | 0.001 |
| IPTCLP, 0–1/2, 3 | 54/30 | 1.027 | 0.304 | 11.445 | 2.793 (1.540–5.064) | 0.001 | 0.999 | 0.304 | 10.763 | 2.715 (1.495–4.930) | 0.001 |
| SUVmax, low/high | 22/62 | 0.959 | 0.405 | 5.619 | 2.609 (1.181–5.766) | 0.018 | 1.020 | 0.421 | 5.878 | 2.773 (1.216–6.325) | 0.015 |
| TMTV, low/high | 43/41 | 1.665 | 0.344 | 23.460 | 5.286 (2.695–10.369) | < 0.001 | 1.608 | 0.342 | 22.095 | 4.994 (2.554–9.766) | < 0.001 |
| TLG, low/high | 35/49 | 1.201 | 0.351 | 11.680 | 3.324 (1.669–6.620) | 0.001 | 1.179 | 0.351 | 11.273 | 3.250 (1.633–6.467) | 0.001 |
Univariate analyses of factors predictive of survival in patients whose scans were evaluated using TMTV and TLG
CI confidence interval, SE standard error, LDH lactate dehydrogenase, ECOG PS Eastern Cooperative Oncology Group performance status, BMB bone marrow biopsy, IPI International Prognostic Index, PIT prognostic index for T-cell lymphoma, IPTCLP International peripheral T cell lymphoma Project, TMTV total metabolic tumor volume, TLG total lesion glycolysis
*P < 0.05